spacer
home > ebr > spring 2018 > therapy at work
PUBLICATIONS
European Biopharmaceutical Review

Therapy at Work

EBR: What is cell therapy?

Dr Daniel Shelly: The use of living human cells as therapeutic treatments can replace lost functionality or introduce a novel function (eg chimeric antigen receptor T-cells to attack tumours). Cell therapies are often classified as either autologous or allogeneic. Autologous cells are obtained from, transformed, and given back to the individual patient, whereas allogeneic cells are sourced from a single donor, grown in large numbers, transformed, and given to multiple patients.

Numerous methods of transformation exist such as using peptides to activate immune cells, using viral vectors to introduce new genetic functions, or gene editing (CRISPR-Cas9) to enhance cellular function. The cell therapy industry is currently at a turning point, driven by significant advances on many fronts, such as a significant amount of product approvals with several more to come, a regulatory recognition of the unique nature of the sector, a financial maturity and investor interest, and finally a general public awareness and interest.

Despite these advances, the sector still needs to optimise several key areas such as manufacture, storage (cryopreservation), formulation, and distribution of such products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Daniel Shelly is Director of business development at Albumedix, responsible for business development and out-licensing of the company’s core technologies and recombinant albumin products for manufacture, stabilisation, and formulation of small molecule, peptide, protein, viral, and cell therapeutics. He spent 10 years in cell culture, vaccine, and gene therapy clinical development and manufacturing. Daniel has authored several peerreviewed articles and book chapters and is an Adjunct Professor in the University of Cincinnati, US, clinical master’s programme, teaching biologics discovery and biotechnology management. He has degrees from Lehigh University (BA), US, The College of William and Mary (MA), US, Florida State (PhD), US, and the University of Cincinnati (MBA), US. Daniel did his post doctorate at the University of California, US, winning the APS Physiological Genomics Fellowship and a National Institutes of Health National Research Service Award.
spacer
Dr Daniel Shelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions Announce a New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2

Schiltigheim, France – 7 June 2022 – Life Science Newswire – ProteoGenix (market-leading antibody provider), Aseem Healthcare (global healthcare company), and Trident Biopharm Solutions (life science consultancy agency) are pleased to announce the development of a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of four fully human neutralizing antibodies (AH-5-COV) was generated by screening the plasma of a COVID-19 survivor using ProteoGenix’s phage display platform. The new treatment is undergoing preclinical evaluation and will be ready to start clinical trials in 2 months.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement